Top stories
PharmaMar, a biopharmaceutical subsidiary of Zeltia SA, has completed enrolment for the randomised Phase IIb trial in resistant/refractory ovarian cancer with PM01183 versus Topotecan...more >>
Corgenix Medical Corporation, a provider of in vitro diagnostic products, has received CE mark notification for the company's ReLASV antigen rapid test for Lassa fever diagnosis...more >>
Eisai Europe Ltd., the UK subsidiary of Eisai Co., Ltd., has filed an application with the European Medicines Agency, or EMA, for anticancer agent Halaven, or eribulin mesylate, requesting an indication expansion of eribulin to contribute to earlier-line treatment of patients with metastatic breast cancer...more >>
Osiris Therapeutics, Inc., a stem cell therapeutic company, has reported that net loss for the first quarter ended March 31, 2013 was $2.73 million, or $0.08 loss per share, compared to a net loss of $1.27 million or $0.04 loss per share, for the same quarter ended March 31, 2012...more >>